This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hussain, M.
Right arrow Articles by Lok, A. S. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hussain, M.
Right arrow Articles by Lok, A. S. F.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, March 2006, p. 1094-1097, Vol. 44, No. 3
0095-1137/06/$08.00+0     doi:10.1128/JCM.44.3.1094-1097.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Sensitive Line Probe Assay That Simultaneously Detects Mutations Conveying Resistance to Lamivudine and Adefovir

Munira Hussain,1 Scott Fung,1 Evelien Libbrecht,2 Erwin Sablon,2 Carmela Cursaro,3 Pietro Andreone,3 and Anna S. F. Lok1*

Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, Michigan,1 Innogenetics NV, Ghent, Belgium,2 Dipartimento di Medicina Interna, Cardioangiologia ed Epatologia, Università di Bologna, Bologna, Italy3

Received 28 November 2005/ Returned for modification 2 December 2005/ Accepted 8 December 2005

The INNO-LiPA HBV DR v2 assay is designed to detect hepatitis B virus mutations conveying resistance to lamivudine and adefovir. Our study confirms that this assay can simultaneously detect the presence of lamivudine and adefovir resistance mutations in clinical samples, has a high degree of concordance with sequencing, and can detect mutants earlier.

* Corresponding author. Mailing address: University of Michigan Medical Center, 1500 East Medical Center Drive, 3912 Taubman Center, Box 0362, Ann Arbor, MI 48109-0362. Phone: (734) 615-4628. Fax: (734) 936-7392. E-mail: aslok{at}umich.edu.

Journal of Clinical Microbiology, March 2006, p. 1094-1097, Vol. 44, No. 3
0095-1137/06/$08.00+0     doi:10.1128/JCM.44.3.1094-1097.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Ntziora, F., Paraskevis, D., Haida, C., Magiorkinis, E., Manesis, E., Papatheodoridis, G., Manolakopoulos, S., Beloukas, A., Chryssoy, S., Magiorkinis, G., Sypsa, V., Hatzakis, A. (2009). Quantitative Detection of the M204V Hepatitis B Virus Minor Variants by Amplification Refractory Mutation System Real-Time PCR Combined with Molecular Beacon Technology. J. Clin. Microbiol. 47: 2544-2550 [Abstract] [Full Text]  
  • Solmone, M., Vincenti, D., Prosperi, M. C. F., Bruselles, A., Ippolito, G., Capobianchi, M. R. (2009). Use of Massively Parallel Ultradeep Pyrosequencing To Characterize the Genetic Diversity of Hepatitis B Virus in Drug-Resistant and Drug-Naive Patients and To Detect Minor Variants in Reverse Transcriptase and Hepatitis B S Antigen. J. Virol. 83: 1718-1726 [Abstract] [Full Text]  
  • Libbrecht, E., Doutreloigne, J., Van De Velde, H., Yuen, M.-F., Lai, C.-L., Shapiro, F., Sablon, E. (2007). Evolution of Primary and Compensatory Lamivudine Resistance Mutations in Chronic Hepatitis B Virus-Infected Patients during Long-Term Lamivudine Treatment, Assessed by a Line Probe Assay. J. Clin. Microbiol. 45: 3935-3941 [Abstract] [Full Text]  
  • Valsamakis, A. (2007). Molecular Testing in the Diagnosis and Management of Chronic Hepatitis B. Clin. Microbiol. Rev. 20: 426-439 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»